Related Experiment Videos
Antianginal Therapy for Stable Ischemic Heart Disease: A Contemporary Review
Santosh K Padala1, Michael P Lavelle2, Mandeep S Sidhu2,3
11 Division of Cardiology, Virginia Commonwealth University, Richmond, VA, USA.
Insights
Optimizing treatment for stable ischemic heart disease (SIHD) involves aggressive pharmacologic strategies to prevent angina and ischemia. Key therapies include beta-blockers, nitrates, and ranolazine for improved quality of life.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic angina pectoris significantly impacts morbidity and mortality, necessitating effective management.
- Suboptimal treatment of stable ischemic heart disease (SIHD) exacerbates patient outcomes.
- Optimal SIHD management aims to prevent angina and ischemia, enhancing both quality and quantity of life.
Purpose of the Study:
- To review current therapeutic approaches for managing chronic angina in SIHD.
- To highlight pharmacologic strategies for optimizing treatment based on individual patient needs.
Main Methods:
- Review of current guidelines and pharmacologic interventions for SIHD.
- Discussion of first-line treatments (beta-blockers) and additional options (nitrates, calcium channel blockers, ranolazine).
- Consideration of European-approved therapies like ivabradine, nicorandil, and trimetazidine.
Main Results:
- Beta-blockers are recommended as first-line treatment for SIHD.
- Nitrates offer acute angina relief and prophylactic benefits.
- Ranolazine is effective for microvascular angina and endothelial dysfunction, and other agents show symptomatic improvement.
Conclusions:
- A multifaceted therapeutic approach, combining lifestyle changes and pharmacologic interventions, is crucial for SIHD management.
- Various medications, used alone or in combination, can effectively manage chronic angina in SIHD patients.
- Individualized treatment strategies are essential for optimizing patient outcomes in SIHD.
Abstract:
Chronic angina pectoris is associated with considerable morbidity and mortality, especially if treated suboptimally. For many patients, aggressive pharmacologic intervention is necessary in order to alleviate anginal symptoms. The optimal treatment of stable ischemic heart disease (SIHD) should be the prevention of angina and ischemia, with the goal of maximizing both quality and quantity of life. In addition to effective risk factor modification with lifestyle changes, intensive pharmacologic secondary prevention is the therapeutic cornerstone in managing patients with SIHD. Current guidelines recommend a multifaceted therapeutic approach with β-blockers as first-line treatment. Another important pharmacologic intervention for managing SIHD is nitrates. Nitrates can provide both relief of acute angina and can be used prophylactically before exposure to known triggers of myocardial ischemia to prevent angina. Additional therapeutic options include calcium channel blockers and ranolazine, an inhibitor of the late inward sodium current, that can be used alone or in addition to nitrates or β-blockers when these agents fail to alleviate symptoms. Ranolazine appears to be particularly effective for patients with microvascular angina and endothelial dysfunction. In addition, certain antianginal therapies are approved in Europe and have been shown to improve symptoms, including ivabradine, nicorandil, and trimetazidine; however, these have yet to be approved in the United States. Ultimately, there are several different medications available to the physician for managing the patient with SIHD having chronic angina, when either used alone or in combination. The purpose of this review is to highlight the most important therapeutic approaches to optimizing contemporary treatment in response to individual patient needs.